China-based ex-hospital digital pharmaceutical service platform YSB Inc. (HKG: 9885) has successfully made its initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company issued 15,808,800 shares, priced at HKD23 per share, resulting in a total capital raise of HKD 363.6 million. Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196), holds a significant stake as the major shareholder with 8.75% of the shares.
Dominant Position in the Ex-Hospital Digital Pharma Market
YSB generated a Gross Merchandise Volume (GMV) of RMB37.8 billion in 2022, capturing 21% of the ex-hospital digital pharmaceutical distribution service market in China. The digital market segment represented 28.2% of the total ex-hospital pharmaceutical distribution market. The company is recognized for its technology-based solutions that connect and empower both upstream pharmaceutical companies and agents, as well as downstream pharmacies and primary medical institutions.
Financial Performance and Growth Prospects
YSB reported revenues of RMB 14.27 billion for the year 2022, marking a significant increase of 41.4%. Despite this growth, the company recorded a loss of RMB1.5 billion. YSB’s IPO is a strategic move to capitalize on its market position and the growing demand for digital pharmaceutical services, aiming to further expand its operations and improve its financial performance.-Fineline Info & Tech
